Risvutatug Rezetecan – BiotechReality – Information Intelligence System for Biopharma

GSK plc (LSE/NYSE: GSK) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to risvutatug rezetecan (also known as Ris-Rez), an investigational B7-H3-targeted antibody-drug conjugate (ADC), for the treatment of small-cell lung cancer (SCLC). This milestone marks the sixth global regulatory designation for the asset, reinforcing its potential as a transformational therapy for aggressive solid tumors. The designation is supported by preliminary clinical data from the Phase I ARTEMIS-001 trial, which demonstrated durable responses in patients with extensive-stage small-cell lung cancer (ES-SCLC). Clinical & Regulatory Milestone Summary The following table outlines the current clinical status and the rapid regulatory momentum of risvutatug rezetecan: FeatureDetailsDrug NameRisvutatug rezetecan (Ris-Rez / GSK’227)Mechanism of ActionB7-H3-targeted ADC with a topoisomerase inhibitor payloadSupporting TrialPhase I ARTEMIS-001 (Early clinical data)Pivotal TrialPhase III Global Trial (NCT07099898) - Started Aug 2025PartnershipExclusive worldwide rights (ex-China) from Hansoh PharmaKey IndicationsSCLC, Prostate Cancer, Colorectal Cancer, Osteosarcoma Read More: GSK’s Novel Antibody-Drug Conjugate, Risvutatug Rezetecan, Granted FDA Orphan Drug Designation for Small-Cell Lung Cancer A Critical Unmet Need in Japan Lung cancer remains the second most common cancer in Japan, with SCLC accounting for approximately 10-15% of all cases. The prognosis for patients with the extensive-stage form of the disease (ES-SCLC) is notably poor: 70% of SCLC patients are diagnosed at the extensive stage. High Relapse Rates: Most patients relapse following initial treatment. Survival Gap: The current median overall survival with standard-of-care for relapsed patients is only 8 months. Deep Insights: Therapeutic Potential and Strategy The granting of ODD in Japan provides GSK with several strategic advantages, including potential tax incentives and a period of market exclusivity, which are critical for rare or difficult-to-treat diseases like SCLC. 1. Targeting B7-H3: Ris-Rez utilizes a fully human monoclonal antibody to target B7-H3, a protein frequently overexpressed in several solid tumors. By linking this to a potent topoisomerase inhibitor payload, the ADC is designed to deliver cell-killing agents directly to the tumor site while minimizing systemic impact. 2. Accelerated Development: GSK’s global Phase III trial (NCT07099898) for relapsed ES-SCLC was initiated in August 2025, just months before this latest Japanese designation. This suggests a highly aggressive development timeline aimed at addressing the 8-month survival barrier currently faced by patients. 3. Expanding Oncology Footprint: Beyond SCLC, GSK is actively investigating Ris-Rez in prostate and colorectal cancers, indicating that the B7-H3 mechanism may serve as a cornerstone for GSK’s broader ADC oncology portfolio. About Risvutatug Rezetecan Risvutatug rezetecan is a novel investigational ADC. Under a licensing agreement with Hansoh Pharma, GSK holds the rights to progress the clinical development and commercialization of the drug globally, excluding Mainland China, Hong Kong, Macau, and Taiwan. GSK

Tag: Risvutatug Rezetecan

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment